CalliSpheres Embolic Microspheres
Launched in 2015, CalliSpheres® Embolic Microspheres incorporates patented technology and has obtained approvals from both the China NMPA and the USA FDA (510k). It is intended to be used for the embolization of arteriovenous malformations (AVMs) and hyper vascular tumors, including uterine fibroids. So far, it’s successfully deployed in thousands of hospitals and primarily employed for the embolization treatment of various solid malignant tumors, including primary liver cancer, metastatic liver cancer, lung cancer, kidney cancer, cervical cancer, prostate cancer, and soft tissue sarcoma.
Optimize Your Embolization Experience:
- Elastic Design for Superior Efficacy: Our embolization microspheres feature an elastic design, providing excellent variable elasticity and ensuring high vascular compliance. Experience superior embolization efficacy that adapts to the unique needs of each procedure.
- Biocompatibility for Peace of Mind: Rest easy with our microspheres' non-inflammatory and non-degradable biocompatibility. Your safety is our priority, and our materials are carefully chosen to enhance compatibility with your body.
- Comprehensive Specifications for Versatility: Choose from a range of six particle sizes, including 70-150μm, 100-300μm, 300-500μm, 500-700μm, 700-900μm, and 900-1200μm. This comprehensive selection ensures that you have the right tools for a diverse array of embolization procedures.
Opt for our CalliSpheres® Embolic Microspheres to elevate your procedures with advanced design, biocompatibility, and versatile specifications.
NMPA: 国械注准20153771072
FDA: K173871
Contact Us
Corporate Office Address: No.100, Tangjiabang Rd., Suzhou Industrial Park, Suzhou, Jiangsu Province,China
Follow Us
